Windtree Therapeutics Faces Delisting After Major BNB Investment

Nasdaq has delisted Windtree Therapeutics, citing a 77% stock decline caused by the company’s decision to invest heavily in Binance Coin (BNB). CEO Jed Latkin confirmed these reports despite the delisting, but shareholders are expressing doubts regarding the strategic shift and potential impact on scientific priorities. The company’s move marks a significant turning point for biotech firms venturing into cryptocurrency. 77% of Windtree’s stock price dropped after the company allocated up to $500 million in BNB tokens. This unexpected turn has raised concerns about financial instability and regulatory scrutiny within the industry.